DeLeonardis, K. et al., “When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?” Journal of Oncology Practice 15, no. 9 (2019): 465–473; Mandelker, D. et al., “Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing,” Journal of the American Medical Association 318, no. 9 (2017): 825–835; Meric-Bernstam, F. et al., “Incidental Germline Variants in 1000 Advanced Cancers on a Prospective Somatic Genomic Profiling Protocol,” Annals of Oncology 27, no. 5 (2016): 795–800; Mody, R.J. et al., “Use of Integrative Clinical Sequencing in the Management of Pediatric Cancer Patients,” Journal of the American Medical Association 314, no. 9 (2015): 1–13; Schrader, K.A. et al., “Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA,” Journal of the American Medical Association Oncology 2, no. 1 (2016): 104–111; Seifert, B.A. et al., “Germline Analysis from Tumor-germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings,” Clinical Cancer Research 22, no. 16 (2016): 4087–4094.CrossRefGoogle Scholar

Clark, D.F., Maxwell, K.N. et al., “Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing,” Journal of Clinical Oncology Precision Oncology 3 (2019): 1–11.Google Scholar

Brodeur, G. M. et al., “Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr.,” Clinical Cancer Research 23, no. 11 (2017): e1–e5; Lawrence, M.S. et al., “Mutational Heterogeneity in Cancer and the Search for New Cancer-associated Genes,” Nature 499, no. 7457 (2013): 214–218; Sweet-Cordero, E.A. and Biegel, J.A., “The Genomic Landscape of Pediatric Cancers: Implications for Diagnosis and Treatment,” Science 363, no. 6432 (2019): 1170–1175; Vogelstein, B. et al., “Cancer Genome Landscapes,” Science 339, no. 6127 (2013): 1546–1558.CrossRefGoogle Scholar

Mandelker, supra note 1; Mody, supra note 1; Zhang, J. et al., “Germline Mutations in Predisposition Genes in Pediatric Cancer,” New England Journal of Medicine 373, no. 24 (2015): 2336–2346.CrossRefGoogle Scholar

Gray, S.W. et al., “Physicians’ Attitudes about Multiplex Tumor Genomic Testing,” Journal of Clinical Oncology 32, no. 13 (2014): 1317–1323; Johnson, L.M. et al., “Integrating Next Generation Sequencing into Pediatric Oncology Practice: An Assessment of Physician Confidence and Understanding of Clinical Genomics,” Cancer 123, no. 12 (2017): 2352–2359.Google Scholar

Kalia, S.S. et al., “Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics,” Genetics in Medicine 19, no. 2 (2017): 249–255.Google Scholar

DeLeonardis, supra note 1.Google Scholar

Meric-Bernstam, supra note 1.Google Scholar

DeLeonardis, supra note 1.Google Scholar

Robson, M. E. et al., “American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility,” Journal of Clinical Oncology 33, no. 31 (2015): 3660–3667.Google Scholar

Li, M. M. et al., “Points to Consider for Reporting of Germline Variation in Patients Undergoing Tumor Testing: A Statement of the American College of Medical Genetics and Genomics (ACMG),” Genetics in Medicine 22, no. 7 (2020): 1142–1148.CrossRefGoogle Scholar

Raymond, V.M. et al., “Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories,” Journal of the National Cancer Institute 108, no. 4 (2016): 1–5.CrossRefGoogle Scholar

Id.Google Scholar

Id.Google Scholar

American Society of Human Genetics Board of Directors and American College of Medical Genetics Board of Directors, “Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents,” American Journal of Human Genetics 57, no. 5 (1995): 1233–1241; Botkin, J.R. et al., “Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents,” American Journal of Human Genetics 97, no. 1 (2015): 6–21; Ross, L.F. et al., “Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children,” Genetics in Medicine 15, no. 3 (2013): 234–245; Ross, L.F. et al., “Erratum: Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children,” Genetics in Medicine 15, no. 4 (2013): 321.Google Scholar

Wilfond, B.S. et al., “Disclosing Secondary Findings from Pediatric Sequencing to Families: Considering the ‘Benefit to Families,’” Journal of Law, Medicine & Ethics 43, no. 3 (2015): 552–558.Google Scholar